Digests

Decision Information

Decision Content

Eli Lilly and Co. v. Novopharm Ltd.

T-2210-93

Rothstein J.

1/2/95

7 pp.

Applicants seeking to file affidavit A to replace affidavit B; or, in the alternative, variation, pursuant to Rule 1733, of order prohibiting use of affidavit B -- Use of affidavit B prohibited due to inability of affiant B to undergo cross-examination as result of illness -- Respondents' willingness to accommodate applicants conditional upon applicants' consent to file affidavit C -- Filing of affidavit C refused by earlier order now under appeal -- Decision to prohibit use of affidavit B made in response to applicants' position they be allowed to use affidavit B with or without cross-examination; applicants not offering any alternative i.e. replacement of affidavit B or modification of cross-examination schedule -- Applicants now not offering any reason for failure to seek replacement of affidavit B during initial motion -- Procedures regarding filing of material pursuant to Regulations often used to obtain tactical advantages; such use to be discouraged -- Proceedings must strike balance between dealing with matters pursuant to Regulations in summary manner and allowing for reasonably complete and relevant information to be included in record -- Applicants seeking Court's indulgence to allow filing of substitute affidavit in place of affidavit ordered to be struck out, yet refusing to accede to introduction of affidavit by respondents -- As applicants adopting strict, intransigent approach, matter to be decided according to such standard -- Court clearly indicating during earlier proceeding applicants to either come to agreement with respondents with respect to material to be filed or run risk application to file affidavit A denied -- Unfair for applicant to now obtain indulgence sought: application dismissed-Variance of order prohibiting use of affidavit B also denied as applicants not satisfying Rule 1733 due diligence requirement-Respondents entitled to costs of motion in any event of cause-Patented Medicines (Notice of Compliance) Regulations, SOR/93-133 -- Federal Court Rules, C.R.C., c. 663, R. 1733.

 You are being directed to the most recent version of the statute which may not be the version considered at the time of the judgment.